Health Economics›Breast cancer›Adjuvant therapy, premenopausal

Adjuvant therapy, premenopausal

Breast cancer · 6 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 1 point

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Leuprolide monotherapy Variant #01	ER	R 253 833	90d	—	—	~2	~R 507 665 PFS proxy · indirect	2
Goserelin and Tamoxifen Variant #01	ER	R 8 293	28d	~13.0 mo	~48.0 mo	~2	~R 16 587 PFS proxy · indirect	2
Tamoxifen and OFS Variant not yet assigned - class-based regimen Partial	ER	R 6 928	28d	—	—	65	R 275 936 PFS proxy	3
Goserelin monotherapy Variant #01	ER	R 2 628	28d	—	—	~2	~R 5 256 indirect	—
Exemestane and OFS Variant #01 Partial	ER	R 2 421	28d	—	—	~65	~R 157 356 indirect	—
Tamoxifen monotherapy Variant #01	ER	R 137	28d	—	—	26	R 3 553 PFS proxy	3

6 of 6 regimens shown